509 related articles for article (PubMed ID: 32645977)
1. Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets.
Alard E; Butnariu AB; Grillo M; Kirkham C; Zinovkin DA; Newnham L; Macciochi J; Pranjol MZI
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645977
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
4. Recent updates on cancer immunotherapy.
Liu M; Guo F
Precis Clin Med; 2018 Sep; 1(2):65-74. PubMed ID: 30687562
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
6. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.
Sivanandam V; LaRocca CJ; Chen NG; Fong Y; Warner SG
Mol Ther Oncolytics; 2019 Jun; 13():93-106. PubMed ID: 31080879
[TBL] [Abstract][Full Text] [Related]
8. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
9. THE ROLE OF IMMUNOTHERAPY IN CANCER TREATMENT: CHECKPOINT INHIBITORS, CAR-T CELLS, AND VACCINES.
Arun J; Singh A; Shashidhar E; Patel G; Verma Y; Sapcota S
Georgian Med News; 2023 Jun; (339):105-112. PubMed ID: 37522784
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
11. Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
Evgin L; Vile RG
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807553
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
13. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
14. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
Zhang Y; Li Y; Chen K; Qian L; Wang P
Cancer Cell Int; 2021 May; 21(1):262. PubMed ID: 33985527
[TBL] [Abstract][Full Text] [Related]
16. Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.
Aitken AS; Roy DG; Bourgeois-Daigneault MC
Biomedicines; 2017 Jan; 5(1):. PubMed ID: 28536346
[TBL] [Abstract][Full Text] [Related]
17. Immuno-Oncology: Emerging Targets and Combination Therapies.
Marshall HT; Djamgoz MBA
Front Oncol; 2018; 8():315. PubMed ID: 30191140
[TBL] [Abstract][Full Text] [Related]
18. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
19. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Sanchez K; Page D; McArthur HL
Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
